Products - Children and young people | Topic

Showing 23 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 December 2024
Maternal and child nutrition
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 January 2025
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment
Status:
In development | In consultation
Programme:
Health technology evaluation
Consultation end date:
17 December 2024
Expected publication date:
24 April 2025
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
School-based interventions: physical and mental health and wellbeing promotion
Status:
In development
Expected publication date:
TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
26 November 2024
Expected publication date:
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 23 products

Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]

Maternal and child nutrition

Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment

Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

School-based interventions: physical and mental health and wellbeing promotion

VTS-270 for treating Niemann-Pick type C1 [ID1267]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Omburtamab for treating relapsed neuroblastoma [ID1664]

Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

Leriglitazone for treating andrenoleukodystrophy [ID3903]

Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]

Vamorolone for treating Duchenne muscular dystrophy [ID4024]

Somapacitan for treating growth hormone deficiency in children [ID6178]

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

Children and young people Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 23 products

Status
1 selected